company background image
FRTX

Fresh Tracks Therapeutics NasdaqCM:FRTX Stock Report

Last Price

US$1.87

Market Cap

US$5.6m

7D

0.9%

1Y

-93.9%

Updated

03 Oct, 2022

Data

Company Financials +
FRTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

FRTX Stock Overview

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.

Fresh Tracks Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fresh Tracks Therapeutics
Historical stock prices
Current Share PriceUS$1.87
52 Week HighUS$34.16
52 Week LowUS$1.67
Beta0.11
1 Month Change-24.90%
3 Month Change-53.02%
1 Year Change-93.89%
3 Year Change-99.00%
5 Year Changen/a
Change since IPO-99.11%

Recent News & Updates

Sep 07

Brickell Biotech changes name to Fresh Tracks Therapeutics

Clinical-stage biotech Brickell Biotech, Inc. (NASDAQ:BBI) announced a major rebranding exercise on Wednesday, renaming its corporate identity to Fresh Tracks Therapeutics, Inc. Accordingly, the company said that BBI’s name, logo, website, and branding would change to reflect the company’s new strategic shift towards autoimmune, inflammatory, and other diseases. In line with the rebranding, the company’s common stock will begin trading under the new Nasdaq ticker symbol “FRTX” from Thursday. Meanwhile, in connection with the rebranding, the company has formed a Scientific Advisory Board (SAB), which comprises experts in immunology and inflammation. SAB will guide the management and board as the company targets autoimmune and inflammatory diseases with early-stage candidate FRTX-02, pre-clinical asset FRTX-10, and the next-generation kinase inhibitor platform. FRTX-02, formerly known as BBI-02, is undergoing a Phase 1 trial for atopic dermatitis with topline data expected in early 2023.

Shareholder Returns

FRTXUS BiotechsUS Market
7D0.9%0.4%-2.5%
1Y-93.9%-25.6%-23.2%

Return vs Industry: FRTX underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: FRTX underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is FRTX's price volatile compared to industry and market?
FRTX volatility
FRTX Average Weekly Movement15.5%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: FRTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: FRTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200916Rob Brownhttps://www.frtx.com

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022.

Fresh Tracks Therapeutics Fundamentals Summary

How do Fresh Tracks Therapeutics's earnings and revenue compare to its market cap?
FRTX fundamental statistics
Market CapUS$5.61m
Earnings (TTM)-US$29.88m
Revenue (TTM)US$4.64m

1.2x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FRTX income statement (TTM)
RevenueUS$4.64m
Cost of RevenueUS$21.22m
Gross Profit-US$16.58m
Other ExpensesUS$13.30m
Earnings-US$29.88m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-9.96
Gross Margin-357.01%
Net Profit Margin-643.48%
Debt/Equity Ratio0%

How did FRTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is FRTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FRTX?

Other financial metrics that can be useful for relative valuation.

FRTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does FRTX's PS Ratio compare to its peers?

FRTX PS Ratio vs Peers
The above table shows the PS ratio for FRTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12.1x
ADXS Advaxis
14.9xn/aUS$3.7m
HSTO Histogen
0.7x-83.3%US$3.4m
USRM U.S. Stem Cell
31xn/aUS$3.9m
HCYT H-CYTE
1.7xn/aUS$2.1m
FRTX Fresh Tracks Therapeutics
1.2x29.0%US$5.4m

Price-To-Sales vs Peers: FRTX is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (11.6x).


Price to Earnings Ratio vs Industry

How does FRTX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: FRTX is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is FRTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FRTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio0.09x

Price-To-Sales vs Fair Ratio: FRTX is expensive based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).


Share Price vs Fair Value

What is the Fair Price of FRTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FRTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FRTX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Fresh Tracks Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FRTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FRTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FRTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FRTX's revenue (29% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: FRTX's revenue (29% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FRTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Fresh Tracks Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-28.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FRTX is currently unprofitable.

Growing Profit Margin: FRTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FRTX is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.

Accelerating Growth: Unable to compare FRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: FRTX has a negative Return on Equity (-191.07%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Fresh Tracks Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: FRTX's short term assets ($18.3M) exceed its short term liabilities ($2.9M).

Long Term Liabilities: FRTX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: FRTX is debt free.

Reducing Debt: FRTX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FRTX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: FRTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26.6% each year


Discover healthy companies

Dividend

What is Fresh Tracks Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Fresh Tracks Therapeutics Dividend Yield vs Market
How does Fresh Tracks Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Fresh Tracks Therapeutics)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Fresh Tracks Therapeutics)n/a

Notable Dividend: Unable to evaluate FRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FRTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as FRTX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Rob Brown (60 yo)

3.75yrs

Tenure

US$1,327,288

Compensation

Attorney. Robert Busard Brown, also known as Rob, serves as Chief Executive Officer and Director at Fresh Tracks Therapeutics, Inc. (formerly known as Brickell Biotech, Inc.) since joining on January 1, 20...


CEO Compensation Analysis

Rob Brown's Compensation vs Fresh Tracks Therapeutics Earnings
How has Rob Brown's remuneration changed compared to Fresh Tracks Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$1mUS$468k

-US$39m

Sep 30 2021n/an/a

-US$41m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$1mUS$450k

-US$21m

Sep 30 2020n/an/a

-US$24m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$24m

Dec 31 2019US$1mUS$450k

-US$14m

Compensation vs Market: Rob's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD781.86K).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: FRTX's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: FRTX's board of directors are seasoned and experienced ( 12.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of FRTX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders29,1511.0%
Private Companies141,3654.7%
Institutions172,9695.8%
General Public2,656,28588.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57.1%.


Top Shareholders

Top 25 shareholders own 11.37% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.52%
Ionic Ventures, LLC
135,444$253.3k0%no data
2.3%
The Vanguard Group, Inc.
68,978$129.0k-0.26%no data
0.8%
Telemetry Investments, L.L.C.
24,111$45.1k-43.05%0.08%
0.72%
Palisade Capital Management LLC
21,567$40.3k0%no data
0.46%
Geode Capital Management, LLC
13,939$26.1k0%no data
0.37%
Millennium Management LLC
11,127$20.8k0%no data
0.37%
Reginald Hardy
11,085$20.7k0%no data
0.23%
Robert Brown
7,037$13.2k0%no data
0.2%
Hardy Capital, Ltd.
5,921$11.1k0%no data
0.16%
BlackRock, Inc.
4,792$9.0k0%no data
0.13%
UBS Asset Management
3,858$7.2k688.96%no data
0.12%
State Street Global Advisors, Inc.
3,489$6.5k158.06%no data
0.11%
Andrew Sklawer
3,325$6.2k0%no data
0.11%
David Mcavoy
3,175$5.9k0%no data
0.1%
PEH Wertpapier AG
3,120$5.8k0%no data
0.1%
Jane Street Group, LLC, Asset Management Arm
3,092$5.8k0%no data
0.097%
Two Sigma Securities, LLC, Asset Management Arm
2,896$5.4k0%no data
0.087%
Northern Trust Global Investments
2,609$4.9k0%no data
0.078%
Journey Strategic Wealth LLC
2,334$4.4k0%no data
0.076%
Deepak Chadha
2,293$4.3k0%no data
0.06%
Citigroup Inc.,Banking and Securities Investments
1,795$3.4k0%no data
0.046%
Thrivent Trust Company, Asset Management Arm
1,366$2.6k0%no data
0.045%
BNY Mellon Asset Management
1,341$2.5k0%no data
0.038%
Tower Research Capital LLC
1,148$2.1k0%no data
0.038%
Dennison Veru
1,129$2.1k0%no data

Company Information

Fresh Tracks Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Fresh Tracks Therapeutics, Inc.
  • Ticker: FRTX
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$5.610m
  • Shares outstanding: 3.00m
  • Website: https://www.frtx.com

Number of Employees


Location

  • Fresh Tracks Therapeutics, Inc.
  • 5777 Central Avenue
  • Suite 102
  • Boulder
  • Colorado
  • 80301
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FRTXNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDSep 2019
VCCDB (Deutsche Boerse AG)YesNew Common StockDEEURSep 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.